The opportunity for financing has arrived!~

Multiple well-known VC firms are seeking high-quality investment targets,

Pipelines of interest include:

(1) Innovative TCE for solid tumors, (2) Innovative radiopharmaceuticals with new targets/new radionuclides, (3) CNS innovative drugs such as Abeta dual-target, (4) Autoimmune innovative drugs with new targets/new MOA.

Biotech companies with relevant products are requested to contact the PharmTimes BD team immediately (BD@drugtimes.cn）！

Main Text:580Word 1Figure

Estimated reading time:2Minute

According to the press release, KY-0301 is a product independently developed by Novatim.The world's first nano bispecific ADC,Obtained U.S. IND approval in 2024 and is currently conducting a Phase I dose-escalation clinical trial in China.

Compared with traditional bispecific ADCs, KY-0301 demonstrates more effective tumor tissue penetration, higher anti-tumor activity, and better safety. Based on the broad-spectrum high expression of MET and EGFR in tumors and innovative differentiated design, this drug is expected to bring new breakthroughs in the treatment of non-small cell lung cancer, colorectal cancer, and head and neck squamous cell carcinoma.

Dr. Guoxiang Wu, founder and chairman of Novatim, stated, "Through our collaboration with Radiance, we will accelerate the global clinical development and commercialization of KY-0301, providing cancer patients with innovative and highly effective treatment options more quickly."

NextYesA MeetingPromotion：

Currently, PharmTimes and the Hepatology New Drug Alliance have decided, in response to industry demand, toNovember 21-22, 2025Held in Shanghai"4th Annual Meeting of the Liver Disease New Drug Alliance and Weight Loss New Drug Forum"Event (Offline). The event is honored to invite multiple senior experts in the industry, focusing on the latest research achievements, clinical practices, and future development directions in the field of liver diseases and related areas. Experts and scholars from hospitals, pharmaceutical companies, CROs, investment institutions, and other organizations will gather to share their industry insights and valuable experiences from different perspectives. Readers who are interested are welcome to stay tuned. The PharmTimes official account will continue to update the latest developments of the conference.

Organizer:Hepatology New Drug Alliance, DrugTimes

Co-organizer:Chronic Disease Management Branch of China Medical Biotechnology Association, Fatty Liver Expert Committee of Chinese Medical Doctor Association, Love Liver Alliance.

Booths are booking up fast! Scan the code to inquire now.

Sponsorship formats include but are not limited to speaking slots, exhibition booths, color pages in the conference brochure, dinner sponsorship, and promotional materials for the conference.

References:

1.Novatim Official WeChat

2.Other Public Information

Breakthrough! Chinese Pharmaceutical Company Develops New Drug for Spinal Cord Injury Regeneration, National Institutes for Food and Drug Control Releases Key Efficacy and Mechanism Results

2025-09-01

New FDA Move! Will MASH Drug Development Enter the "Non-Invasive Era"?

2025-08-30

Huino Pharmaceuticals Completes First Patient Dosing in Phase II Clinical Study of Herpes Simplex Virus Inhibitor HN0037

2025-08-29

Copyright Statement/Disclaimer

This is a compiled article.

This article is for informational exchange only and does not provide any commercial, medical, or investment advice.

The images, videos, fonts, music, and other materials in the article are either authorized genuine works purchased by Yaotimes, or from the WeChat public image library, or taken from the company's official website/network. Some materials are used under the CC0 protocol, and the copyright belongs to the owner. Yaotimes makes every effort to acknowledge the sources.

If you have any questions, please contact us.

Sincerely grateful!

DrugTimes Official Website: www.drugtimes.cn

Contact Information:

Phone: 13651980212

WeChat: 27674131

Email: contact@drugtimes.cn

Click here,Check out the exciting events from previous Hepatology New Drug Alliance activities!